New Weight-Loss drug SYH9017 enters human testing in china
NCT ID NCT06830343
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called SYH9017 in 66 Chinese adults who are overweight or obese. The main goal is to check the drug's safety and how the body processes it after single and multiple doses. Participants will receive either the drug or a placebo, and researchers will monitor side effects and drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection help tackle obesity and diabetes? a safety trial begins
- Can a single injection of SYH2082 help tackle obesity? a first-in-human trial puts safety to the test.
- App sends mindfulness exercises right after weight regain to keep dieters on track
- Sleep program aims to reduce pregnancy risks in african american women
- Could a Muscle-Building drug boost weight loss? new trial tests bimagrumab with semaglutide
- Weekly shot could help shed pounds in obesity trial